A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site
A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site
复制标题
DOI：
10.1093/jjco/hyh124
复制
发表时间：
2004-11-01
影响因子：
2.4
通讯作者：
Kim, Heung-Tae
中科院分区：
文献类型：
--
作者：
Park, Yeon Hee;Ryoo, Baek-Yeol;Kim, Heung-Tae
目的：目的：评价紫杉醇联合顺铂治疗原发部位不明恶性肿瘤（CUP）的疗效和毒副反应。疗效进行了评估，在反应率，无进展生存期和总survival.Methods：37例CUP患者在2001年1月至2003年9月在韩国癌症中心医院。紫杉醇175 mg/m2静脉滴注，21天为1周期。顺铂（60 mg/m（2）i. v.）结果：37例患者中，腺癌亚型31例。26例可测量病灶患者的总体缓解率为42% [95%置信区间（CI）23-61%]。6名患者病情稳定，9名患者病情进展。至进展的中位时间为4个月（95% CI 1.3-6.8）。中位总生存期为11个月（95% CI 8.3-13.5）。主要毒副反应为神经病变和中性粒细胞减少。4级中性粒细胞减少发生在10例，但发热性中性粒细胞减少被认为是在four.Conclusions：这种联合紫杉醇和顺铂方案耐受性良好，令人鼓舞的水平的有效性与CUP患者。
Objective: We evaluated the efficacy and toxicity of combined paclitaxel and cisplatin chemotherapy in patients with cancer of unknown primary site (CUP). Efficacy was evaluated in terms of response rate, progression-free survival and overall survival.Methods: Thirty-seven patients with CUP were enrolled between January 2001 and September 2003 at Korea Cancer Center Hospital. The patients received 21-day cycles of paclitaxel (175 mg/m(2) i.v.) with cisplatin (60 mg/m(2) i.v.) given on the first day.Results: Of the 37 patients, 31 had adenocarcinoma subtypes. The overall response rate of 26 patients with measurable lesions was 42% [95% confidence interval (Cl) 23-61%]. Stable disease was seen in six patients and progressive disease in nine. Median time to progression was 4 months (95% Cl 1.3-6.8). Median overall survival was 11 months (95% Cl 8.3-13.5). The major toxicities were neuropathy and neutropenia. Grade 4 neutropenia occurred in 10 patients, but febrile neutropenia was seen in four.Conclusions: This combined paclitaxel and cisplatin regimen was well tolerated with an encouraging level of effectiveness for patients with CUP.